Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

FOLFIRI regimen

View Patient Information
A regimen consisting of leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan that can be used in the treatment of appendiceal, small bowel, pancreatic and occult primary adenocarcinoma; colorectal, esophageal and esophagogastric junction, gastric, and hepatobiliary cancers; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:fluorouracil-folinic acid-irinotecan
fluorouracil/folinic acid/irinotecan
fluorouracil/leucovorin/irinotecan
FOLinic acid-fluorouracil-IRInotecan regimen
folinic acid/fluorouracil/irinotecan regimen
Abbreviation:FOLFIRI
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search